Is Kanna (Sceletium tortuosum) Legal in Idaho? (2026)

Instrument

Schedule I hallucinogenic substances; simulated controlled substance definition

Source

https://legislature.idaho.gov/wp-content/uploads/statutesrules/idstat/Title37/T37CH27.pdf

Retrieved

2026-10-29

Fingerprint

9655493402bd031f

(d) Hallucinogenic substances. Any material, compound, mixture or
preparation that contains any quantity of the following hallucinogenic
substances, their salts, isomers and salts of isomers, unless specifically
excepted, whenever the existence of these salts, isomers, and salts of
isomers is possible within the specific chemical designation (for purposes
of this subsection only, the term "isomer" includes the optical, position
and geometric isomers):

(1)
Dimethoxyphenethylamine, or any compound not specifically
excepted or listed in another schedule that can be formed from
dimethoxyphenethylamine by replacement of one (1) or more hydrogen
atoms with another atom(s), functional group(s) or substructure(s)
including, but not limited to, compounds such as DOB, DOC, 2C-B,
25B-NBOMe;
(2) Methoxyamphetamine or any compound not specifically excepted or
listed in another schedule that can be formed from methoxyamphetamine
by replacement of one (1) or more hydrogen atoms with another atom(s),
functional group(s) or substructure(s) including, but not limited to,
compounds such as PMA and DOM;
(3) 5-methoxy-3,4-methylenedioxy-amphetamine;
(4) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(5) Amphetamine or methamphetamine with a halogen substitution on the
benzyl ring, including compounds such as fluorinated amphetamine and
fluorinated methamphetamine;
(6) 3,4-methylenedioxy amphetamine (MDA);
(7) 3,4-methylenedioxymethamphetamine (MDMA);
(8) 3,4-methylenedioxy-N-ethylamphetamine ( N-ethyl MDA, MDE, MDEA);
(9) N-hydroxy-3,4-methylenedioxyamphetamine ( N-hydroxy MDA);
(10) 3,4,5-trimethoxy amphetamine;
(11) 5-methoxy-N,N-dimethyltryptamine ( 5-MeO-DMT);
(12) Alpha-ethyltryptamine ( etryptamine, AET);
(13) Alpha-methyltryptamine (AMT);
(14) Bufotenine;
(15) Diethyltryptamine (DET);
(16) Dimethyltryptamine (DMT);
(17) Ibogaine;
(18) Lysergic acid diethylamide (LSD);
(19) Marihuana (marijuana);
(20) Mescaline;
(21) Methoxetamine;
(22) Parahexyl;
(23) Peyote;

12

(24) N-ethyl-3-piperidyl benzilate;
(25) N-methyl-3-piperidyl benzilate;
(26) Para-methoxymethamphetamine (PMMA);
(27) Psilocybin;
(28) Psilocyn;
(29) Tetrahydrocannabinols or synthetic equivalents of the substances
contained in the plant, or in the resinous extractives of Cannabis, sp.
and/or synthetic substances, derivatives, and their isomers with simi-
lar chemical structure such as the following:

i.
Tetrahydrocannabinols, except for the permitted amount of
tetrahydrocannabinol found in industrial hemp, or nabiximols
in a drug product approved by the United States food and drug
administration:

a. ∆ 1 cis or trans tetrahydrocannabinol, and their opti-
cal isomers, excluding dronabinol in sesame oil and encapsu-
lated in either a soft gelatin capsule or in an oral solution
in a drug product approved by the U.S. Food and Drug Adminis-
tration.
b. ∆ 6 cis or trans tetrahydrocannabinol, and their optical
isomers.
c. ∆ 3,4 cis or trans tetrahydrocannabinol, and its optical
isomers. (Since nomenclature of these substances is not in-
ternationally standardized, compounds of these structures,
regardless of numerical designation of atomic positions are
covered.)
d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methy-
loctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-
1-o1)],
tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric
isomers (HU211 or dexanabinol).

6aR-trans-3-(1,1-dimethylhep-

known

also

as

ii. The following synthetic drugs:

cycloalkenyl,

aryl)methane,

a. Any compound structurally derived from (1H-indole-3-
yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-in-
dole-3-yl)(cycloalkyl,
or
(1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl, methyl
or dimethyl butanoate, amino-methyl (or dimethyl)-1-oxobu-
tan-2-yl) carboxamide by substitution at the nitrogen atoms
of the indole ring or carboxamide to any extent, whether
or not further substituted in or on the indole ring to any
extent, whether or not substituted to any extent in or on the
cycloalkyl, cycloalkenyl, aryl ring(s) (substitution in the
ring may include, but is not limited to, heteroatoms such as
nitrogen, sulfur and oxygen).
b. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluo-
ropentyl)-1 H-indazole-3-carboxamide (5F-AB-PINACA).
c. N-ethylpentylone (ephylone).
d. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1
zole-3-carboxamide (4-cn-cumyl-BUTINACA).
e. 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-
one (Cumyl Pegaclone).
f. Ethyl
ido)-3,3-dimethylbutanoate (5F-EDMB-PINACA).

2-(1-(5-fluoropentyl)-1H-indazole-3carboxam-

H-inda-

13

MMB-

(Methyl

FUBINACA

2-(1-(4-fluoroben-

2-(1-(5-fluoropentyl)-1H-indole-3-carboxam-

2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-

2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-

2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxam-

2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-

Methyl 3,3-dimethyl-2-((1-(pent-4-en-1-yl)-1H-inda-

g. Ethyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-
3,3-dimethylbutanoate (5F-EDMB-PICA).
h. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3tetram-
ethylcyclopropyl)methanone (FUB-144).
i. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-inda-
zole-3-carboxamide (5f-cumyl-pinaca; SGT-25).
j. (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
H-pyrrolo[2.3-B]pyridine-3-carboxamide(5fcumyl-P7AICA).
k. FUB-AMB,
zyl)-1H-indazole-3-carboxamido)-3-methylbutanoate.
l. MMB-FUBICA (Methyl 2-(1-(4-Fluorobenzyl)-1H-Indole-3-
carboxamido)-3-methyl butanoate).
m.
zole-3-carboxamido)butanoate (MDMB-4EN-PINACA).
n. Methyl
ido)-3-methylbutanoate (MMB-CHMICA, AMB-CHMICA).
o. Methyl
ido)-3,3-dimethylbutanoate (MDMB-CHMICA, MMB-CHMINACA).
p. Methyl
ido-3,3-dimethylbutanoate (MDMB-FUBINACA).
q. Methyl 2-[[1-(4-Fluorobutyl)Indole-3-Carbonyl]Amino]-
3,3-Dimethyl-Butanoate (4F-MDMB-BUTICA, 4F-MDMB-BICA).
r. Methyl
ido)-3,3-dimethylbutanoate (5F-MDMB-PICA, 5F-MDMB-2201).
s. Methyl
ido)-3,3-dimethylbutanoate (5F-ADB, 5F-MDMB-PINACA).
t. Methyl
ido)-3-methylbutanoate (5F-AMB).
u.
Indazole-3-carboxamide (ADB-BUTINACA).
v. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluo-
robenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA).
w.
en-1-yl)-1H-indazole-3-carboxamide (ADB-4EN-PINACA).
x. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide (FUB-AKB48; FUB-APINACA).
y. N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide (5F-APINACA, 5F-AKB48).
z. N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(Cyclohexyl-
methyl)-1H-indazole-3-carboxamide (AB-CHMINACA).
aa. Naphthalen-1-yl
boxylate (NM2201; CBL2201).
bb. Any compound structurally derived from 3-(1-naph-
thoyl)pyrrole by substitution at the nitrogen atom of the
pyrrole ring to any extent, whether or not further sub-
stituted in the pyrrole ring to any extent, whether or not
substituted in the naphthyl ring to any extent.
cc. Any compound structurally derived from 1-(1-naphthyl-
methyl)indene by substitution at the 3-position of the in-
dene ring to any extent, whether or not further substituted
in the indene ring to any extent, whether or not substituted
in the naphthyl ring to any extent.

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-

N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-

2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-

1-(5-fluoropentyl)-1H-indole-3-car-

14

from

derived

compound

structurally

3-pheny-
dd. Any
lacetylindole by substitution at the nitrogen atom of the
indole ring to any extent, whether or not further sub-
stituted in the indole ring to any extent, whether or not
substituted in the phenyl ring to any extent.
ee. Any compound structurally derived from 2-(3-hydroxy-
cyclohexyl)phenol by substitution at the 5-position of the
phenolic ring to any extent, whether or not substituted in
the cyclohexyl ring to any extent.
ff. Any compound structurally derived from 3-(benzoyl)in-
dole structure with substitution at the nitrogen atom of
the indole ring to any extent, whether or not further sub-
stituted in the indole ring to any extent and whether or not
substituted in the phenyl ring to any extent.
gg. [2,3-dihydro-5-methyl-3-(4-morpholinyl-
methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
napthalenylmethanone (WIN-55,212-2).
hh. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-
243).
ii. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-
5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahy-
drophenanthridin-1-yl]acetate (CP 50,5561).

(30) Ethylamine analog of phencyclidine: N-ethyl-1-phenylcy-
clohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcy-
clohexyl) ethylamine, cyclohexamine, PCE;
(31) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl) -
pyrrolidine, PCPy, PHP;
(32) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-
piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;
(33) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name: TCPy;
(34) Spores or mycelium capable of producing mushrooms that contain
psilocybin or psilocin.

(ff) "Simulated controlled substance" means a substance that is not a
controlled substance, but which by appearance or representation would lead
a reasonable person to believe that the substance is a controlled substance.

Instrument

Possession of inhalants by minors

Source

https://legislature.idaho.gov/statutesrules/idstat/Title18/T18CH15/SECT18-1502B/

Retrieved

2026-10-31

Fingerprint

46e620ef6dda95e4

18-1502B.  
Possession of inhalants by minors. 
Whenever a person under the age of eighteen (18) years is in possession and uses an aerosol spray product or other inhalant, that is not used pursuant to the instructions or prescription of a licensed health care provider or that is not used pursuant to the manufacturer’s label instructions, for the purpose of becoming under the influence of such substance; such person shall be guilty of a misdemeanor, and upon conviction, may be punished by a fine not in excess of three hundred dollars ($300), or by thirty (30) days in a juvenile detention facility or by both or may be subject to the provisions of
chapter 5, title 20
, Idaho Code.

For the purposes of this section, the term “inhalant” means any glue, cement or other substance containing one (1) or more of the following chemical compounds:  acetone and acetate, amyl nitrite or amyl nitrate or their isomers, benzene, butyl alcohol, butyl nitrite, butyl nitrate or their isomers, ethyl alcohol, ethyl nitrite or ethyl nitrate, ethylene dichloride, isobutyl alcohol, methyl alcohol, methyl ethyl ketone, n-propyl alcohol, pentachlorophenol, petroleum ether, propyl nitrite or propyl nitrate or their isomers, toluene or xylene or other chemical substance capable of causing a condition of intoxication, inebriation, excitement, stupefaction or the dulling of the brain or nervous system as a result of the inhalation of the fumes or vapors of such chemical substance.

History:

[18-1502B, added 1993, ch. 154, sec. 1, p. 390; am. 2004, ch. 23, sec. 4, p. 27.]

Instrument

Schedule I, hallucinogenic substances

Source

https://legislature.idaho.gov/statutesrules/idstat/Title37/T37CH27/SECT37-2705/

Retrieved

2026-11-06

Fingerprint

5bd87cf120dddac6

(d)  Hallucinogenic substances. Any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this subsection only, the term "isomer" includes the optical, position and geometric isomers):

(1)  Dimethoxyphenethylamine, or any compound not specifically excepted or listed in another schedule that can be formed from dimethoxyphenethylamine by replacement of one (1) or more hydrogen atoms with another atom(s), functional group(s) or substructure(s) including, but not limited to, compounds such as DOB, DOC, 2C-B, 25B-NBOMe;

(2)  Methoxyamphetamine or any compound not specifically excepted or listed in another schedule that can be formed from methoxyamphetamine by replacement of one (1) or more hydrogen atoms with another atom(s), functional group(s) or substructure(s) including, but not limited to, compounds such as PMA and DOM;

(3)  5-methoxy-3,4-methylenedioxy-amphetamine;

(4)  5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);

(5)  Amphetamine or methamphetamine with a halogen substitution on the benzyl ring, including compounds such as fluorinated amphetamine and fluorinated methamphetamine;

(6)  3,4-methylenedioxy amphetamine (MDA);

(7)  3,4-methylenedioxymethamphetamine (MDMA);

(8) 3,4-methylenedioxy-N-ethylamphetamine (N-ethyl MDA, MDE, MDEA);

(9)  N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy MDA);

(10) 3,4,5-trimethoxy amphetamine;

(11) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);

(12) Alpha-ethyltryptamine (etryptamine,  AET);

(13) Alpha-methyltryptamine (AMT);

(14) Bufotenine;

(15) Diethyltryptamine (DET);

(16) Dimethyltryptamine (DMT);

(17) Ibogaine;

(18) Lysergic acid diethylamide (LSD);

(19) Marihuana (marijuana);

(20) Mescaline;

(21) Methoxetamine;

(22) Parahexyl;

(23) Peyote;

(24) N-ethyl-3-piperidyl benzilate;

(25) N-methyl-3-piperidyl benzilate;

(26) Para-methoxymethamphetamine (PMMA);

(27) Psilocybin;

(28) Psilocyn;

(29) Tetrahydrocannabinols or synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure such as the following:

i.  Tetrahydrocannabinols, except for the permitted amount of tetrahydrocannabinol found in industrial hemp, or nabiximols in a drug product approved by the United States food and drug administration:

a.  ∆
1
 cis or trans tetrahydrocannabinol, and their optical isomers, excluding dronabinol in sesame oil and encapsulated in either a soft gelatin capsule or in an oral solution in a drug product approved by the U.S. Food and Drug Administration.

b.  ∆
6
 cis or trans tetrahydrocannabinol, and their optical isomers.

c.  ∆
 3,4
 cis or trans tetrahydrocannabinol, and its optical isomers. (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions are covered.)

d.  [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-o1)], also known as 6aR-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric isomers (HU211 or dexanabinol).

ii.  The following synthetic drugs:

a. Any compound structurally derived from (1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methane, or (1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl, methyl or dimethyl butanoate, amino-methyl (or dimethyl)-1-oxobutan-2-yl) carboxamide by substitution at the nitrogen atoms of the indole ring or carboxamide to any extent, whether or not further substituted in or on the indole ring to any extent, whether or not substituted to any extent in or on the cycloalkyl, cycloalkenyl, aryl ring(s) (substitution in the ring may include, but is not limited to, heteroatoms such as nitrogen, sulfur and oxygen).

b. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1 H-indazole-3-carboxamide (5F-AB-PINACA).

c. N-ethylpentylone (ephylone).

d. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide (4-cn-cumyl-BUTINACA).

e.  5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-one (Cumyl Pegaclone).

f. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate (5F-EDMB-PINACA).

g.  Ethyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (5F-EDMB-PICA).

h. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3tetramethylcyclopropyl)methanone (FUB-144).

i. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (5f-cumyl-pinaca; SGT-25).

j. (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2.3-B]pyridine-3-carboxamide(5fcumyl-P7AICA).

k. FUB-AMB, MMB- FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate.

l.  MMB-FUBICA (Methyl 2-(1-(4-Fluorobenzyl)-1H-Indole-3-carboxamido)-3-methyl butanoate).

m.  Methyl 3,3-dimethyl-2-((1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4EN-PINACA).

n. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA, AMB-CHMICA).

o. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA, MMB-CHMINACA).

p. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido-3,3-dimethylbutanoate (MDMB-FUBINACA).

q.  Methyl 2-[[1-(4-Fluorobutyl)Indole-3-Carbonyl]Amino]-3,3-Dimethyl-Butanoate (4F-MDMB-BUTICA, 4F-MDMB-BICA).

r. Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (5F-MDMB-PICA, 5F-MDMB-2201).

s. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-ADB, 5F-MDMB-PINACA).

t. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB).

u.  N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-Indazole-3-carboxamide (ADB-BUTINACA).

v. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA).

w.  N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide (ADB-4EN-PINACA).

x. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (FUB-AKB48; FUB-APINACA).

y. N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA, 5F-AKB48).

z. N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(Cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA).

aa. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201; CBL2201).

bb. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring to any extent, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent.

cc. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring to any extent, whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent.

dd. Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring to any extent, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent.

ee. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring to any extent, whether or not substituted in the cyclohexyl ring to any extent.

ff. Any compound structurally derived from 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring to any extent, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

gg. [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone (WIN-55,212-2).

hh. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-243).

ii. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate (CP 50,5561).

(30) Ethylamine analog of phencyclidine: N-ethyl-1-phenylcyclohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

(31) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl) -pyrrolidine, PCPy, PHP;

(32) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;

(33) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name: TCPy;

(34) Spores or mycelium capable of producing mushrooms that contain psilocybin or psilocin.